RESULTS: In total, 113 patients were included, 95.6% of whom had stage IV disease. Thirty six patients received gemcitabine plus platinum as the first-line treatment, 32 received pemetrexed plus platinum, 11 received EGFR-TKIs and the rest received docetaxel, paclitaxel, novelbine and etc. Forty four patients received oral EGFR-TKIs as the second-line treatment. At the end of follow-up (2015-3-30), 91 patients were dead and 22 patients were alive or lost follow up. The median survival of this whole cohort was 20.0m (95%CI, 16.1m-24.0m,). The overall survival was not associated with the chemotherapy drugs used in the first-line treatment. The patients (19.0m, 95%CI; 11.4m-26.5m) used pemetrexed plus platinum lived no longer than those who used other regimens (20.5m, 95%CI; 13.4m-27.4m) (p=0.272). In the gemcitabine plus platinum group, the median survival was 19.9m (95%CI; 9.2m-30.6m), which was not longer than other groups (20.0m, 95%CI; 15.4m-27.4m) (p=0.404). Those who had a chance to take EGFR-TKIs lived numerically longer than never; the median survival was 24.8m (19.1m-30.5m, 95%CI) and 16.3m (12.7m-19.9m, 95%CI), respectively. However, the overall difference was not significant (p=0.184).